» Articles » PMID: 34338882

Immune Checkpoint Inhibitor Treatment Induces Colitis with Heavy Infiltration of CD8 + T Cells and an Infiltration Pattern That Resembles Ulcerative Colitis

Overview
Journal Virchows Arch
Date 2021 Aug 2
PMID 34338882
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Colitis is a common, but poorly understood, adverse event of immune checkpoint inhibitors that are standard-of-care for an expanding range of cancer types. This explorative study aimed to describe the immune infiltrates in the colon from individuals developing checkpoint inhibitor colitis and compare them to well-known immunophenotypes of acute graft-versus-host disease, ulcerative colitis, and Crohn's disease. Colon biopsies (n = 20 per group) of patients with checkpoint inhibitor colitis, acute graft-versus-host disease, ulcerative colitis and Crohn's disease, all colitis treatment-naïve, and of individuals with a normal colon were analyzed using immunohistochemistry: CD8 for cytotoxic T cells, CD4 for T helper cells, and CD68 to identify cells of macrophage lineage. CD8 + T cell, CD4 + T cell, and CD68 + cell counts were performed. Cell infiltration was scored as scattered/patchy or band-like in the superficial and deep gut mucosa. Checkpoint inhibitor colitis was found to be heavily infiltrated by CD8 + T cells. Comparative analysis between groups showed that both CD8 + T cell counts (P < 0.01) and immune cell infiltration patterns in checkpoint inhibitor colitis were most similar to those observed in ulcerative colitis, with a deep band-like CD4 + T cell infiltration pattern and a superficial band-like CD68 + cell infiltration pattern in both. In conclusion, this is the first immunohistopathological study comparing infiltrate characteristics of checkpoint inhibitor colitis, acute graft-versus-host disease, ulcerative colitis, and Crohn's disease. Checkpoint inhibitor colitis samples are heterogeneous, heavily infiltrated by CD8 + T cells, and show an immune cell infiltration pattern that is more similar to ulcerative colitis than to colonic acute graft-versus-host disease or colonic Crohn's disease.

Citing Articles

Tertiary Lymphoid Structures and Immunotherapy: Challenges and Opportunities.

Ruddle N Methods Mol Biol. 2024; 2864:299-312.

PMID: 39527229 DOI: 10.1007/978-1-0716-4184-2_16.


Atezolizumab-Induced Ulcerative Colitis in Patient with Hepatocellular Carcinoma: Case Report and Literature Review.

Kim H, Shin Y, Yoo H, Kim J, Yoo J, Kim S Medicina (Kaunas). 2024; 60(9).

PMID: 39336463 PMC: 11433725. DOI: 10.3390/medicina60091422.


Bronchoalveolar lavage fluid analysis in patients with checkpoint inhibitor pneumonitis.

Chen R, Shi Y, Fang N, Shao C, Huang H, Pan R Cancer Immunol Immunother. 2024; 73(11):235.

PMID: 39271538 PMC: 11399518. DOI: 10.1007/s00262-024-03834-y.


Bile acid metabolism modulates intestinal immunity involved in ulcerative colitis progression.

Huang H, Yan S, Guo T, Hua Q, Wang Y, Xu S Heliyon. 2024; 10(14):e34352.

PMID: 39114032 PMC: 11305184. DOI: 10.1016/j.heliyon.2024.e34352.


Role of the microbiota in response to and recovery from cancer therapy.

Blake S, Wolf Y, Boursi B, Lynn D Nat Rev Immunol. 2023; 24(5):308-325.

PMID: 37932511 DOI: 10.1038/s41577-023-00951-0.


References
1.
Tandon P, Bourassa-Blanchette S, Bishay K, Parlow S, Laurie S, McCurdy J . The Risk of Diarrhea and Colitis in Patients With Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis. J Immunother. 2018; 41(3):101-108. DOI: 10.1097/CJI.0000000000000213. View

2.
Thomas A, Ma W, Wang Y . Ustekinumab for Refractory Colitis Associated with Immune Checkpoint Inhibitors. N Engl J Med. 2021; 384(6):581-583. DOI: 10.1056/NEJMc2031717. View

3.
Beardslee T, Draper A, Kudchadkar R . Tacrolimus for the treatment of immune-related adverse effects refractory to systemic steroids and anti-tumor necrosis factor α therapy. J Oncol Pharm Pract. 2018; 25(5):1275-1281. DOI: 10.1177/1078155218793709. View

4.
Martins F, Sykiotis G, Maillard M, Fraga M, Ribi C, Kuntzer T . New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. Lancet Oncol. 2019; 20(1):e54-e64. DOI: 10.1016/S1470-2045(18)30828-3. View

5.
Geukes Foppen M, Rozeman E, van Wilpe S, Postma C, Snaebjornsson P, van Thienen J . Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open. 2018; 3(1):e000278. PMC: 5786923. DOI: 10.1136/esmoopen-2017-000278. View